Jeanmarie Guenot is one of the most notable professionals in the pharmacological and biotechnology business. She has worked in various capacities for a number of companies, both private and public, for the last 20 years. She holds a Ph.D. from the University of California, San Francisco and an MBA from the Wharton School at the University of Pennsylvania. Her educational background focused on physical and medicinal chemistry.
What Is JeanMarie Guenot’s Career Like?
Guenot’s career started off at Hoffman-La Roche in Basel and Shanghai. Working as the principle scientist in preclinical research and development, she developed drugs for infection, metabolic illnesses, autoimmune ailments, and oncology. She also served as vice head of Group and Business Expansion at PDL Biopharma where she was involved in facilitating licensing, mergers and procurement, and managing of Research and Development of commercial production portfolios.
More to that, Guenot initiated, put up and ran SKS Ocular, a start-up Ophthalmic firm incubator, which centers on waterless AMD, continued relief ocular drug delivery machinery and therapeutics for optical infections, glaucoma, and macular deterioration.
JeanMarie Guenot then went into business at Atlas venture where she succeeded venture key reserves and built life education companies, working at the Board of Directors level. She is currently the President and CEO of Amphivena Therapeutics, Inc. The company is engaged in creating ground-breaking bifunctional antibody therapies for hematologic malignancies.
Publications Authored by JeanMarie Guenot
JeanMarie Guenot’s Biggest Accomplishments?
While working at Hoffman-La Roche, she pushed for the development and commercialization of the drug Biogen Idec-PDL. Ultimately, this endeavor would see her receive the Bio Professional Network’s Groundbreaking Bio-Partnering Honor in the year 2005. She also received the Deal of Merit from the Accrediting Executives Society in the year 2006. GuenotLLC.com outlines that Jeanmarie was also the key participant in the sale of PDL’s commercial and manufacturing businesses, as well as a member of PDL’s Executive Team and Portfolio Management. In addition, she commanded the Biogen Idec-PDL Agreement and was also an affiliate of the Cooperative Steering Board.
JeanMarie Guenot has made significant strides in medicine and her continued dedication to research and development in different areas is nothing short of remarkable.